2023 annual financial data
Iovance Biotherapeutics 2023 Operating margin
Direct answer
Operating margin was -38,734.99%.
Operating income was -460,559,000 USD and net income was -444,037,000 USD.
Operating cash flow was -361,820,000 USD.
Get free Iovance Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,189,000 USD
- Operating income
- -460,559,000 USD
- Net income
- -444,037,000 USD
- Operating cash flow
- -361,820,000 USD